Akari Therapeutics (AKTX) just unveiled an update.
Akari Therapeutics, Plc is slashing its workforce by 67%, including some top management roles, as part of a strategic shift to streamline operations and reduce costs, especially those associated with its suspended HSCT-TMA program. The company anticipates incurring between $3.1 and $3.2 million in expenses from this downsizing, with payments expected to continue until the end of 2024. While these figures are based on current assumptions, actual costs could vary, and unforeseen expenses might arise from the restructuring process.
For a thorough assessment of AKTX stock, go to TipRanks’ Stock Analysis page.
